Yourway and Firma Clinical Research to Administer Coordinated Supply Delivery for Home-Health Trial Visits
Yourway, an integrated courier and clinical packager in the global clinical trials supply chain market, and Firma Clinical Research, the niche service provider for patient-centric home healthcare, are joining forces to provide coordinated supply and product deliveries and administration services for virtual/decentralized clinical trials. The collaboration between the two clinical study service providers supports patient retention and compliance, while also helping CROs and sponsors improve the efficiency of clinical trial management.
Yourway and Firma are working together to ensure a seamless process for the delivery of supplies and drugs needed for in-home visits to clinical trial patients. Clinical products and equipment are coordinated to be sent directly to the patient. In addition, collected bodily samples and other materials are shipped from the patient’s home through a courier. In-home patient care is performed by an approved healthcare provider.
This patient-centric approach of Yourway and Firma assures delivery, protocol compliance and data quality. The collaboration between the two companies extends through 2020.
“Yourway has served the biopharma industry for more than two decades, and we are proud to collaborate with Firma Clinical to help improve the patient experience for in-home health visits for clinical trials,” says Gulam Jaffer, President, Yourway. “We offer direct-to-patient and direct-from-patient services globally, including shipments that require ambient to frozen temperatures and controlled substances. These services are making virtual and decentralized clinical trials possible.”
“Firma is committed to the needs of patients, sponsors and healthcare professionals by providing in-home care for clinical trials that often involve investigational products (IP),” says Michael Woods, CEO, Firma Clinical Research. “Firma has completed thousands of home health visits in 45 countries, and about 40 percent include the administration of IPs. We take a patient-centric approach to our services and often work with advocacy groups to collect patient survey data for sponsors.”
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
